“We plan to cover one third of the Romanian anti-diabetic market within five years. This type of drug currently makes up some 25 percent of turnover,” said Corporate Manager Daniel Popescu. The company will launch a program to inform diabetics about this disease. Its portfolio includes some ten anti-diabetic drugs, and three new products will be launched in 2008.
Eli Lilly will also launch one drug each for the central nervous system and the treatment of leukemia.
The Regional Manager for South East Europe, Camilla Shen, said the company will invest 15-20 percent more this year in Romania.
Popescu added that the Romanian anti-diabetic drug market is worth some RON 200 million (€54.62 mln). Eli Lilly’s main competitors on the local market are Novartis, Sanofi-Aventis and Novo Nordisk.
Eli Lilly plans to become Romanian anti-diabetic drug market leader
Publicat la 25.05.2008, 21:00:00
Acest articol nu reprezintă consultanță financiară.
Newsletter zilnic money.ro
BET, curs valutar, știrea zilei — în 2 minute, înainte de 7:00.
Articole înrudite
Actualitate
Luca Niculescu, desemnat premier. Fostul ambasador la Paris are 10 zile să ceară votul Parlamentului
Actualitate
Proiect de lege privind zilierii pentru ONG-uri și culte. De ce se opune Guvernul
Actualitate
Curg banii europeni în Republica Moldova după reformele de aderare. UE mai virează 157 de milioane de euro
Actualitate
Ion Țiriac: „Vă dau cuvântul meu de onoare că nu știu ce avere am”
Actualitate